S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY

• A. Sehgal,
• D. Hoda,
• P. A. Riedell,
• N. Ghosh,
• M. Hamadani,
• G. C. Hildebrandt,
• J. E. Godwin,
• P. Reagan,
• N. Wagner-Johnston,
• J. Essell,
• R. Nath,
• S. R. Solomon,
• R. Champion,
• E. Licitra,
• S. Fanning,
• N. Gupta,
• R. Dubowy,
• A. D’Andrea,
• L. Wang,
• L. I. Gordon

Affiliations

A. Sehgal

1 University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh

D. Hoda

2 Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City

P. A. Riedell

3 University of Chicago Comprehensive Cancer Center, Chicago

N. Ghosh

4 Levine Cancer Institute, Atrium Health, Charlotte

M. Hamadani

5 BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee

G. C. Hildebrandt

6 Markey Cancer Center, University of Kentucky, Lexington

J. E. Godwin

7 Providence Cancer Center, Earle A. Chiles Research Institute, Portland

P. Reagan

8 University of Rochester Medical Center, Rochester

N. Wagner-Johnston

9 Johns Hopkins Hospital, Baltimore

J. Essell

10 Oncology Hematology Care, Cincinnati

R. Nath

11 Banner MD Anderson Cancer Center, Gilbert

S. R. Solomon

12 Northside Hospital Cancer Institute, Atlanta

R. Champion

13 Norton Cancer Institute, Louisville

E. Licitra

14 Astera Cancer Care, East Brunswick

S. Fanning

15 Prisma Health, Greenville

N. Gupta

16 Stanford Cancer Genetics Clinic, Palo Alto

R. Dubowy

17 Bristol Myers Squibb, Seattle, United States of America

A. D’Andrea

18 Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland

L. Wang

17 Bristol Myers Squibb, Seattle, United States of America

L. I. Gordon

19 Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, United States of America